SG11201402986RA - Kinase inhibitors - Google Patents

Kinase inhibitors

Info

Publication number
SG11201402986RA
SG11201402986RA SG11201402986RA SG11201402986RA SG11201402986RA SG 11201402986R A SG11201402986R A SG 11201402986RA SG 11201402986R A SG11201402986R A SG 11201402986RA SG 11201402986R A SG11201402986R A SG 11201402986RA SG 11201402986R A SG11201402986R A SG 11201402986RA
Authority
SG
Singapore
Prior art keywords
parma
palermo
international
chiesi
via palermo
Prior art date
Application number
SG11201402986RA
Inventor
Niel Monique Bodil Van
Nicholas Charles Ray
Lilian Alcaraz
Terry Aaron Panchal
Andrew Stephen Robert Jennings
Elisabetta Armani
Andrew Peter Cridland
Christopher Hurley
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of SG11201402986RA publication Critical patent/SG11201402986RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 June 2013 (13.06.2013) WIPOIPCT (10) International Publication Number WO 2013/083606 A1 (51) International Patent Classification: C07D 471/04 (2006.01) A61P11/00 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/EP2012/074450 (22) International Filing Date: 5 December 2012 (05.12.2012) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 11192894.1 9 December 2011 (09.12.2011) EP 12187932.4 10 October 2012 (10.10.2012) EP (71) Applicant: CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, 1-43100 Parma (IT). (72) Inventors: VAN NIEL, Monique Bodil; Chiesi Farma- ceutici S.P.A., Via Palermo, 26/A, 1-43100 Parma (IT). RAY, Nicholas Charles; Chiesi Farmaceutici S.P.A., Via Palermo, 26/A, 1-43100 Parma (IT). ALCARAZ, Lilian; Chiesi Farmaceutici S.P.A., Via Palermo, 26/A, 1-43100 Parma (IT). PANCHAL, Terry Aaron; Chiesi Farmaceut­ ici S.P.A., Via Palermo, 26/A, 1-43100 Parma (IT). JEN­ NINGS, Andrew Stephen Robert; Chiesi Farmaceutici S.P.A., Via Palermo, 26/A, 1-43100 Parma (IT). AR­ MANI, Elisabetta; Via Palermo, 26/A, 1-43100 Parma (IT). CRIDLAND, Andrew Peter; Chiesi Farmaceutici S.P.A., Via Palermo, 26/A, 1-43100 Parma (IT). HUR­ LEY, Cristopher; Chiesi Farmaceutici S.P.A., Via Palermo, 26/A, 1-43100 Parma (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.R.L., Via Plinio, 63,1-20129 Milano (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: KINASE INHIBITORS o m oo © rn CJ Y-R (I) (57) Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R , 2 W, A, Y and R 1 are as defined O in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the res - piratory tract.
SG11201402986RA 2011-12-09 2012-12-05 Kinase inhibitors SG11201402986RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11192894 2011-12-09
EP12187932 2012-10-10
PCT/EP2012/074450 WO2013083606A1 (en) 2011-12-09 2012-12-05 Kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201402986RA true SG11201402986RA (en) 2014-12-30

Family

ID=47469888

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201402986RA SG11201402986RA (en) 2011-12-09 2012-12-05 Kinase inhibitors
SG10201604656YA SG10201604656YA (en) 2011-12-09 2012-12-05 Kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201604656YA SG10201604656YA (en) 2011-12-09 2012-12-05 Kinase inhibitors

Country Status (19)

Country Link
US (2) US8835431B2 (en)
EP (1) EP2788348B1 (en)
JP (1) JP6145849B2 (en)
KR (1) KR20140105459A (en)
CN (1) CN103974953B (en)
AR (1) AR089113A1 (en)
AU (1) AU2012347352B2 (en)
BR (1) BR112014013177A2 (en)
CA (1) CA2860479A1 (en)
HK (1) HK1199873A1 (en)
IL (1) IL232959A (en)
MX (1) MX351958B (en)
MY (1) MY167216A (en)
PH (1) PH12014501278A1 (en)
RU (1) RU2623734C9 (en)
SG (2) SG11201402986RA (en)
TW (1) TWI568732B (en)
WO (1) WO2013083606A1 (en)
ZA (1) ZA201404157B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858420A1 (en) * 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
EP2788349B1 (en) 2011-12-09 2016-10-26 Chiesi Farmaceutici S.p.A. Kinase inhibitors
SG11201402986RA (en) * 2011-12-09 2014-12-30 Chiesi Farma Spa Kinase inhibitors
CA2914432A1 (en) * 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
AR107165A1 (en) * 2015-12-23 2018-03-28 Chiesi Farm Spa QUINASE INHIBITORS
US10364245B2 (en) * 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
PL3691620T3 (en) 2017-10-05 2022-11-21 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN108424372B (en) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 Process for purifying 2, 2, 2-trifluoro-N- [ (S) -4-carbonyltetrahydronaphthalen-1-yl ] -acetamide
RU2676692C1 (en) * 2018-08-01 2019-01-10 Российская Федерация, От Имени Которой Выступает Министерство Промышленности И Торговли Российской Федерации Method of producing n-phenyl-2-naftylamine
JP7301362B2 (en) 2019-10-31 2023-07-03 株式会社タカゾノ Core body
JP7323926B2 (en) 2019-10-31 2023-08-09 株式会社タカゾノ winding body
JP7333062B2 (en) 2019-10-31 2023-08-24 株式会社タカゾノ winding body

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (en) 1999-05-11 2003-08-29 Pfizer Products Inc. Process for the synthesis of nucleosite analogues
MXPA02000314A (en) 1999-07-09 2004-06-22 Boehringer Ingelheim Pharma Novel process for synthesis of heteroaryl-substituted urea compounds.
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
JP4486817B2 (en) 2001-12-20 2010-06-23 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 1,4-dihydro-1,4-diphenylpyridine derivative
BRPI0407384A (en) 2003-02-14 2006-02-21 Pfizer Prod Inc pyridines-triazoles as anti-inflammatory compounds
PL214032B1 (en) * 2003-03-03 2013-06-28 Array Biopharma P38 inhibitors and methods of use thereof
WO2005018624A2 (en) * 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
SE0302487D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
ATE400567T1 (en) 2004-06-23 2008-07-15 Lilly Co Eli KINASE INHIBITORS
ATE412652T1 (en) 2004-08-12 2008-11-15 Pfizer TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS INHIBITORS OF P38 MAP KINASE
EP1781655A2 (en) 2004-08-18 2007-05-09 Pharmacia & Upjohn Company LLC Triazolopyridine compounds useful for the treatment of inflammation
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc Enzyme modulators and treatments
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
WO2006133006A2 (en) 2005-06-03 2006-12-14 Bayer Healthcare Ag 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
WO2007091152A1 (en) * 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2008043019A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
MX2009003650A (en) 2006-10-06 2009-04-22 Abbott Lab Novel imidazothiazoles and imidazoxazoles.
ES2320955B1 (en) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF 3 - ((1,2,4) TRIAZOLO (4,3-A) PIRIDIN-7-IL) BENZAMIDA.
CN101636397B (en) 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 Urea compounds, preparation methods and pharmaceutical uses thereof
US20110207729A1 (en) 2007-08-10 2011-08-25 Astellas Pharma Inc. Bicyclic acylguanidine derivative
WO2009048474A1 (en) 2007-10-12 2009-04-16 Pharmacopeia, Inc. 2,7,9-substituted purinone derivatives for immunosuppression
KR20110020906A (en) 2008-06-11 2011-03-03 액테리온 파마슈티칼 리미티드 Tetrazole compounds as orexin receptor antagonists
TWI496779B (en) 2008-08-19 2015-08-21 Array Biopharma Inc Triazolopyridine compounds as pim kinase inhibitors
CN102307581B (en) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 Imidazopyrazine SYK inhibitors
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
CN102395586A (en) 2009-02-17 2012-03-28 奇斯药制品公司 TRiazolopyridine derivatives as p38 map kinase inhibitors
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
WO2011018916A1 (en) 2009-08-12 2011-02-17 コニカミノルタホールディングス株式会社 Method for manufacturing display panel
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
EP2556068B1 (en) * 2010-04-08 2019-01-23 Respivert Limited P38 map kinase inhibitors
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
SG11201402986RA (en) * 2011-12-09 2014-12-30 Chiesi Farma Spa Kinase inhibitors
CA2858420A1 (en) * 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
EP2788349B1 (en) * 2011-12-09 2016-10-26 Chiesi Farmaceutici S.p.A. Kinase inhibitors

Also Published As

Publication number Publication date
JP2015502948A (en) 2015-01-29
RU2014123031A (en) 2016-01-27
CN103974953A (en) 2014-08-06
MX351958B (en) 2017-11-06
EP2788348A1 (en) 2014-10-15
BR112014013177A2 (en) 2017-06-13
SG10201604656YA (en) 2016-07-28
US8835431B2 (en) 2014-09-16
HK1199873A1 (en) 2015-07-24
RU2623734C9 (en) 2017-09-18
US20130150361A1 (en) 2013-06-13
US20140343055A1 (en) 2014-11-20
TWI568732B (en) 2017-02-01
AU2012347352B2 (en) 2016-12-15
TW201331200A (en) 2013-08-01
RU2623734C2 (en) 2017-06-29
IL232959A0 (en) 2014-08-03
AU2012347352A1 (en) 2014-07-03
MX2014006629A (en) 2014-07-09
IL232959A (en) 2016-11-30
PH12014501278B1 (en) 2014-09-08
KR20140105459A (en) 2014-09-01
ZA201404157B (en) 2015-12-23
AR089113A1 (en) 2014-07-30
WO2013083606A1 (en) 2013-06-13
EP2788348B1 (en) 2016-10-19
MY167216A (en) 2018-08-14
PH12014501278A1 (en) 2014-09-08
CA2860479A1 (en) 2013-06-13
CN103974953B (en) 2016-06-29
US9029373B2 (en) 2015-05-12
JP6145849B2 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
SG11201402986RA (en) Kinase inhibitors
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201804934PA (en) Novel Compounds
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201805380YA (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
CA2859619C (en) Bromodomain inhibitors
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201407988UA (en) Process for improved opioid synthesis
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
SG11201804048WA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors